Cell Therapeutics, Inc. Letterhead]Equity/Long-Term Incentive Award Agreement • May 2nd, 2013 • Cell Therapeutics Inc • Pharmaceutical preparations • Washington
Cell Therapeutics, Inc. Letterhead]Equity/Long-Term Incentive Award Agreement • May 2nd, 2013 • Cell Therapeutics Inc • Pharmaceutical preparations
Reference is made to the performance-based stock award (the “Award”) granted to you by Cell Therapeutics, Inc. (the “Company”), effective as of January 3, 2012 (the “Effective Date”) and evidenced by the Equity/Long-Term Incentive Award Agreement between you and the Company entered into following the Effective Date (the “Award Agreement”). This letter amendment (this “Amendment”) sets forth our agreement to amend the Award Agreement on the terms set forth herein. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Award Agreement.
WHOLESALE DISTRIBUTION AGREEMENTWholesale Distribution Agreement • May 2nd, 2013 • Cell Therapeutics Inc • Pharmaceutical preparations
THIS WHOLESALE DISTRIBUTION AGREEMENT (this “Agreement”) is made as of March 26, 2013 (the “Effective Date”) by and between CTI LIFE SCIENCES LIMITED, a limited company incorporated under the laws of England and Wales, having a registered office at Highlands House, Basingstoke Road, Spencer Wood, Reading, Berkshire RG7 1NT United Kingdom (“CTILS”), which is a wholly owned subsidiary of CELL THERAPEUTICS, INC., a Washington corporation, with its principal place of business at 3101 Western Avenue, Suite 600, Seattle, Washington 98121, U.S.A. (“CTI”) and MAX PHARMA GMBH, a corporation duly organized and existing under the laws of the Federal Republic of Germany, having its principal office at Am Gewerbegebiet 5, 95185 Gattendorf, Germany (“Wholesaler”). CTILS and Wholesaler are referred to herein as the “Parties,” and each individually as a “Party.”
AMENDMENT to EMPLOYMENT AGREEMENTEmployment Agreement • May 2nd, 2013 • Cell Therapeutics Inc • Pharmaceutical preparations
THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is dated as of March 21, 2013, by and between Cell Therapeutics, Inc., a Washington corporation (the “Company”), and James A. Bianco, M.D. (the “Executive”).
